Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.56 |
| ▸ | DAO | P14920 | 5/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 4/20 | 0.46 |
| ▸ | PDE9A | O76083 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.46 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.46 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30159638 | 1.00 | HCAR2 (0.56) | HCAR2DAOCYP3A4PDE5APDE9A | |
| SCHEMBL14719290 | 0.87 | HCAR2 (0.48) | HCAR2DAOCYP3A4EGLN1PARP1 | |
| SCHEMBL16231965 | 0.85 | HTR2B (0.47) | HCAR2DAOEGLN1PARP1 | |
| SCHEMBL14719355 | 0.84 | LMNA (0.49) | DAOEGLN1 | |
| SCHEMBL14719472 | 0.83 | PARP1 (0.52) | HCAR2DAOPARP1 | |
| SCHEMBL14719140 | 0.83 | DAO (0.51) | DAOPARP1 | |
| SCHEMBL30107651 | 0.83 | DAO (0.51) | DAOPARP1 | |
| SCHEMBL14719553 | 0.83 | HCAR2 (0.56) | HCAR2DAOPARP1 | |
| SCHEMBL30107633 | 0.83 | HCAR2 (0.56) | HCAR2DAOPARP1 | |
| SCHEMBL14718571 | 0.80 | DAO (0.53) | DAOPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | claimed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | claimed |
| EP-3113778-B1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICALS CO (JP) | 2018-06-06 | — | — | EP | claimed |
| US-9931340-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | claimed |
| EP-2748149-B9 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-11-15 | — | — | EP | claimed |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | claimed |
| US-20170014407-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-19 | — | — | US | claimed |
| EP-3113778-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | Takeda Pharmaceutical Company Limited (JP) | 2017-01-11 | — | — | EP | claimed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | claimed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | claimed |
| WO-2015132608-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTION OR TREATMENT OF AN ATAXIC DISORDER | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-11 | — | — | WO | claimed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | claimed |
| EP-2748149-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2014-07-02 | — | — | EP | claimed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | claimed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | claimed |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-07 | — | — | US | disclosed |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | HCAR2 1251/4885DAO 4565/4885CYP3A4 15/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HCAR2 2398/4885DAO 2/4885CYP3A4 29/4885 |
| US-20170014407-A1 | PYRIDAZINE DERIVATIVES FOR USE IN THE PREVENTON OR TREATMENT OF AN ATAXIC DISORDER | ATXN2, CLN6, ATXN10 | HCAR2 841/4885DAO 1144/4885CYP3A4 2380/4885 |
| US-12186313-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | HCAR2 2398/4885DAO 2/4885CYP3A4 29/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HCAR2 2398/4885DAO 2/4885CYP3A4 29/4885 |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | HCAR2 2398/4885DAO 2/4885CYP3A4 29/4885 |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HCAR2 2398/4885DAO 2/4885CYP3A4 29/4885 |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | HCAR2 2398/4885DAO 2/4885CYP3A4 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.